Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Thurs Jan 9th, the US Stock Markets will be closed in observance of a national day of mourning for former President Jimmy Carter. Read the press release here. Regular trading hours will resume tomorrow.

Gsk Plc ADR (GSK)

Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 69,948,568
  • Shares Outstanding, K 2,072,550
  • Annual Sales, $ 37,725 M
  • Annual Income, $ 6,130 M
  • EBIT $ 4,926 M
  • EBITDA $ 7,779 M
  • 60-Month Beta 0.63
  • Price/Sales 1.79
  • Price/Cash Flow 6.58
  • Price/Book 4.04

Options Overview Details

View History
  • Implied Volatility 25.18% ( +0.17%)
  • Historical Volatility 20.78%
  • IV Percentile 72%
  • IV Rank 48.77%
  • IV High 46.75% on 10/09/24
  • IV Low 4.64% on 08/29/24
  • Put/Call Vol Ratio 1.07
  • Today's Volume 2,255
  • Volume Avg (30-Day) 4,005
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 144,646
  • Open Int (30-Day) 130,065

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.54
  • Number of Estimates 4
  • High Estimate 0.63
  • Low Estimate 0.49
  • Prior Year 0.72
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.04 +2.15%
on 12/20/24
36.28 -6.99%
on 12/09/24
-0.82 (-2.37%)
since 12/06/24
3-Month
32.83 +2.82%
on 11/15/24
41.80 -19.26%
on 10/09/24
-4.27 (-11.23%)
since 10/08/24
52-Week
32.83 +2.82%
on 11/15/24
45.92 -26.51%
on 05/15/24
-5.89 (-14.86%)
since 01/08/24

Most Recent Stories

More News
Moderna, Novavax Stocks Climb Pre-Market On Growing Bird Flu Concerns: Retail Engagement Soars

The U.S. government has been preparing for potential outbreaks, awarding $306 million last week for avian flu preparedness.

NVAX : 9.60 (-11.23%)
MRNA : 43.17 (-9.17%)
GSK : 33.75 (-1.00%)
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NYSE:ABBV),(NASDAQ:CRDF) EQNX::TICKER_END

ONCY : 0.8680 (-5.08%)
AZN : 66.58 (-0.09%)
ABBV : 178.50 (-0.57%)
ONC.TO : 1.30 (+3.17%)
GSK : 33.75 (-1.00%)
CRDF : 3.90 (-4.99%)
3 Pharma Stocks to Buy as California Sounds the Alarm on Bird Flu Cases

The bird flu crisis is creating investment opportunities in the pharmaceutical sector, with Sanofi, GSK, and CSL Limited emerging as top picks.

GSK : 33.75 (-1.00%)
CSLLY : 89.5800 (+0.71%)
SNY : 49.23 (-1.28%)
Moderna Stock Down 39% in Three Months: Buy the Dip or Wait?

Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have been sliding down over the past few years due to waning demand for the vaccine.In...

MRK : 99.85 (-1.16%)
MRNA : 43.17 (-9.17%)
GSK : 33.75 (-1.00%)
PFE : 26.86 (-1.00%)
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?

Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have gained 15.4% in a year against the industry’s decline of 10.8%. The stock has...

MRK : 99.85 (-1.16%)
GILD : 89.14 (-1.64%)
GSK : 33.75 (-1.00%)
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END

ONCY : 0.8680 (-5.08%)
NVS : 100.22 (+1.25%)
ONC.TO : 1.30 (+3.17%)
PFE : 26.86 (-1.00%)
GSK : 33.75 (-1.00%)
BMY : 56.81 (-0.58%)
Top Research Reports for Netflix, BP & Constellation Energy

Wednesday, December 11, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Netflix, Inc....

NFLX : 875.00 (-0.48%)
TSLA : 394.94 (+0.15%)
CEG : 243.84 (-4.61%)
TRV : 242.77 (+0.45%)
GSK : 33.75 (-1.00%)
BP : 31.12 (-2.23%)
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?

GSK GSK stock has declined 20.2% in the past three months compared with a decrease of 12.3% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the chart below....

HLN : 9.49 (+0.32%)
MRNA : 43.17 (-9.17%)
GSK : 33.75 (-1.00%)
SNY : 49.23 (-1.28%)
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD

GSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD) treatment for...

ALNY : 240.55 (+1.95%)
GILD : 89.14 (-1.64%)
GSK : 33.75 (-1.00%)
PFE : 26.86 (-1.00%)
Gilead Stock Surges 44.2% in 6 Months: Time to Buy or Sell?

Biotech giant Gilead Sciences, Inc.’s GILD shares have risen 44.2% in the past six months compared with the industry’s growth of 1.1%. The stock has also outperformed the sector and the S&P 500. It...

MRK : 99.85 (-1.16%)
GILD : 89.14 (-1.64%)
GSK : 33.75 (-1.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 34.51
2nd Resistance Point 34.21
1st Resistance Point 33.98
Last Price 33.75
1st Support Level 33.46
2nd Support Level 33.16
3rd Support Level 32.93

See More

52-Week High 45.92
Fibonacci 61.8% 40.92
Fibonacci 50% 39.38
Fibonacci 38.2% 37.83
Last Price 33.75
52-Week Low 32.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar